Clinical trial
Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs…
NCT00197275 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00197275 |
|---|---|
| Title | Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants |
| Official title | Demonstrate Lot-to-lot Consistency of Final Production Method of GSK Biologicals' Hib-MenAC Vaccine Mixed Extemporaneously With Tritanrix™-HepB & Demonstrate Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Healthy Infants at 2, 4 and 6 Months |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Whole Cell Pertussis, Diphtheria |
| Intervention type | Biological |
| Interventions | Hib-MenAC mixed with Tritanrix™-HepB |
| Enrollment | 800 |
| Start date | Feb 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Oct 7, 2016 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: